Search
ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation
He describes the trial's success in patients with ESR1 mutations, and discusses the steps ahead for both this program and the protein...
Jun 1
SF Healthcare Week: The CEO of Arvinas talks protein degradation, including about the industry's first phase 3 readout that is upcoming this quarter
John Houston describes what he believes are the keys to protein degradation, and discusses the company's monotherapy and combination...
Jan 15
.png){kind=logo}
